Zhi Tong Cai Jing·2026-01-09 14:24Core Viewpoint - Revolution Medicines (RVMD.US) is experiencing significant stock price increases due to acquisition talks with Merck (MRK.US), with potential deal valuations between $28 billion and $32 billion, marking it as one of the largest pharmaceutical transactions since Pfizer's $43 billion acquisition of Seagen at the end of 2023 [1] Group 1 - Revolution Medicines' stock rose nearly 15% in pre-market trading and has accumulated a 35% increase over the past two trading days [1] - Merck is reportedly in discussions to acquire Revolution Medicines, focusing on a deal valued between $28 billion and $32 billion [1] - If the acquisition is finalized, it would represent one of the largest pharmaceutical industry deals since the end of 2023 [1] Group 2 - AbbVie (ABBV.US) was also reported to be in "deep" negotiations to acquire Revolution Medicines, with a potential valuation exceeding $20 billion, although AbbVie later denied any ongoing negotiations [1]